Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia | Zendy

Leanne M. Ward | Zendy; Francis H. Glorieux | Zendy; Michael P. Whyte | Zendy; Craig Munns | Zendy; Anthony A. Portale | Zendy; Wolfgang Högler | Zendy; Jill H. Simmons | Zendy; Gary S. Gottesman | Zendy; Raja Padidela | Zendy; Noriyuki Namba | Zendy; Hae Il Cheong | Zendy; Ola Nilsson | Zendy; Meng Mao | Zendy; Angel Chen | Zendy; Alison Skrinar | Zendy; Mary Scott Roberts | Zendy; Erik A. Imel | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia

Author(s) -

Leanne M. Ward,

Francis H. Glorieux,

Michael P. Whyte,

Craig Munns,

Anthony A. Portale,

Wolfgang Högler,

Jill H. Simmons,

Gary S. Gottesman,

Raja Padidela,

Noriyuki Namba,

Hae Il Cheong,

Ola Nilsson,

Meng Mao,

Angel Chen,

Alison Skrinar,

Mary Scott Roberts,

Erik A. Imel

Publication year - 2022

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/clinem/dgac296

Subject(s) - medicine , hypophosphatemia , rickets , pediatrics , context (archaeology) , vitamin d and neurology , vitamin d deficiency , older people , physical therapy , gerontology , paleontology , biology

Younger age at treatment onset with conventional therapy (phosphate salts and active vitamin D; Pi/D) is associated with improved growth and skeletal outcomes in children with X-linked hypophosphatemia (XLH). The effect of age on burosumab efficacy and safety in XLH is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research